Robins Kaplan LLP Named a Recommended Firm for Hatch-Waxman by LMG Life Sciences

December 1, 2016

Robins Kaplan LLP is pleased to announce that LMG Life Sciences has recommended the firm as a top Hatch-Waxman patent litigation firm for generic pharmaceutical companies. LMG Life Sciences also named two members of Robins Kaplan’s Hatch-Waxman Litigation practice group “Life Science Stars.” Recipients include:

The recognition is a reflection of the firm’s successful representation of generic pharmaceutical companies, as well as the sophisticated legal and scientific understanding of the attorneys who practice in the field. Recipients were chosen based on nearly 1,000 interviews and surveys, including firm-wide surveys, interviews with individual attorneys and clients, and a review of public information.

Jake M. Holdreith

Partner

Managing Partner, Minneapolis Office
Member of Executive Board

Ronald J. Schutz

Partner

Immediate Past Chairman
Member of Executive Board

Related Publications

September 18, 2024
Astellas Pharma, Inc. v. Sandoz Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 9, 2024
Purdue Pharma L.P v. Accord Healthcare Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 4, 2024
Exeltis USA, Inc. v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
August 28, 2024
Teva Branded Pharm. Products R&D, Inc. v. Deva Holding A.S.
GENERICally Speaking Hatch Waxman Bulletin
August 13, 2024
Allergan USA, Inc. v. MSN Labs. Private Ltd.
GENERICally Speaking Hatch Waxman Bulletin
Back to Top